| Metric | Q4'25 | Q1'26 | Change |
|---|---|---|---|
| FFO per share diluted as adjusted | $2.16 (Q4) | $1.73 (Q1) | 20% sequential decline |
| Occupancy | 90.9% (Q4) | 87.7% (Q1) | 320 bps plunge on known expirations |
| Leasing volume | 1.2M SF (Q4) | 647K SF (Q1) | 46% sequential drop |
| Same-property NOI | Down 6% (Q4) | Down 11.9% (Q1) | Deterioration accelerated |
| Public biotech leasing | Some activity (Q4) | 0 SF (Q1) | First zero quarter in company history |
| Development leasing | Not disclosed | 118K SF executed + 276K SF LOIs | 394K SF total momentum |
| Capitalized interest | $82M (Q4) | $70M (Q1) | $12M decline from project pauses |
| G&A expense savings | $51.3M annual (2025) | $7.4M vs Q4 average | Continued cost discipline |
| Market share capture | Not disclosed | 2x market share in top 3 markets | Boston 153%, SF Bay 253%, San Diego 208% |
| Year-end 2026 occupancy guidance | 88.5% midpoint | 87% midpoint | 150 bps cut |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.